<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04723875</url>
  </required_header>
  <id_info>
    <org_study_id>2020-S113</org_study_id>
    <nct_id>NCT04723875</nct_id>
  </id_info>
  <brief_title>Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline</brief_title>
  <official_title>Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline：A Prospective Multicenter Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Women's Hospital School Of Medicine Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Obstetrics &amp; Gynecology Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, phase 3 randomized controlled clinical trial. Cervical cancer patients&#xD;
      who undergo radical surgery but do not meet criteria of adjuvant therapy according to NCCN&#xD;
      guideline are enrolled to receive adjuvant chemotherapy. The primary endpoint was&#xD;
      disease-free survival (DFS) rate at 3 year. The secondary endpoints were 5-year DFS, overall&#xD;
      survival (OS) and safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>3 year</time_frame>
    <description>DFS is defined as the time interval between the date of random assignment and the date of the first documented evidence of relapse at any site or death related to cancer (including toxicity), whichever occurred first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival （OS）</measure>
    <time_frame>3 year</time_frame>
    <description>OS is defined as the time from the date of randomization until death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year DFS/OS</measure>
    <time_frame>5 years</time_frame>
    <description>DFS is defined as the time interval between the date of random assignment and the date of the first documented evidence of relapse at any site or death related to cancer (including toxicity), whichever occurred first. OS is defined as the time from the date of randomization until death of any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">306</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Adjuvant chemotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant will receive 3 cycles of adjuvant chemotherapy if having any of the following factors；participant will receive 6 cycles of adjuvant chemotherapy if having ≥2 of the following factors.&#xD;
Risk factors: (1) Deep cervical invasion（≥ 2/3）；（2）Differentiation grade 2-3；（3）Lymphatic vascular space infiltration；（4）Adenocarcinoma or adenosquamous carcinoma；（5）Tumor size ≥ 2cm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The participants receive no intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel or docetaxel + Cisplatin or carboplatin</intervention_name>
    <description>Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.</description>
    <arm_group_label>Adjuvant chemotherapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with 2018 FIGO staged IB1，IB2, IIA1 cervical cancer.&#xD;
&#xD;
          2. The initial treatment was radical hysterectomy + pelvic lymphadenectomy by laparotomy&#xD;
             or laparoscopy with cervical cancer foci sealed before dissection of the vagina and&#xD;
             without uterine manipulator.&#xD;
&#xD;
          3. Postoperative pathological diagnosis was cervical squamous cell carcinoma, cervical&#xD;
             adenosquamous cell carcinoma or cervical adenocarcinoma.&#xD;
&#xD;
          4. Assessment of risk factors not meeting Sedlis criteria （NCCN guideline），but having one&#xD;
             of following factors ：（1）Deep stromal infiltration（≥2/3 layer）；（2）histopathological&#xD;
             differentiation grade G2 ~ G3；（3）Lymph-vascular space invasion ；（4）Adenocarcinoma or&#xD;
             adenosquamous cell carcinoma；（5）Tumor size ≥2cm.&#xD;
&#xD;
          5. Age：18-70 years old.&#xD;
&#xD;
          6. WBC≥3.5*10^9/L, NEU≥1.5*10^9/L, Platelet≥80×10^9 /L; AST and ALT ≤1.5 times normal&#xD;
             upper limit; Total bilirubin ≤1.5 times the upper limit of normal value; serum&#xD;
             creatinine and blood urea nitrogen ≤the upper limit of normal value.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group score 0-1.&#xD;
&#xD;
          8. Well-compliance and willing to keep in touch.&#xD;
&#xD;
          9. Willing to participate in this study, and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Postoperative pathology has high-risk factors（lymph node metastasis, parametrial&#xD;
             infiltration or positive surgical margin）or meets Sedlis criteria.&#xD;
&#xD;
          2. Participate in other clinical trials at the same time.&#xD;
&#xD;
          3. Comorbidity including but not limited to: heart diseases (grade III-IV cardiac&#xD;
             insufficiency (NYHA standard); central nervous system diseases or nonfunctional&#xD;
             behavior; hematological system diseases; liver or kidney malformation or history of&#xD;
             surgery.&#xD;
&#xD;
          4. Persons without disposing capacity.&#xD;
&#xD;
          5. Drug and/or alcohol abuse.&#xD;
&#xD;
          6. Unable or unwilling to sign informed consents.&#xD;
&#xD;
          7. Not eligible for the study judged by researchers.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ding Ma, M.D., PhD</last_name>
    <phone>0086-27-83662681</phone>
    <email>dma@tjh.tjmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ding Ma, M.D., PhD</last_name>
      <phone>0086-27-83662681</phone>
      <email>dma@tjh.tjmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Ding Ma</investigator_full_name>
    <investigator_title>Director of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

